GLP-1受体激动剂-话题@MedSci

#GLP-1受体激动剂#

37篇内容 | 2832人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2232676, encodeId=d02122326e6c6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a> <a href='/topic/show?id=1b2d120502dd' target=_blank style='color:#2F92EE;'>#青少年患者#</a>, objectTitle=JAMA 子刊：青少年使用GLP-1受体激动剂的现状与共病特征分析, objectType=article, longId=847970, objectId=56d484e9706b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401021/1729522865589_5121051.png, objectUrl=/article/show_article.do?id=56d484e9706b, replyNumber=0, likeNumber=17, createdTime=2024-10-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=56d484e9706b, moduleTitle=JAMA 子刊：青少年使用GLP-1受体激动剂的现状与共病特征分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56d484e9706b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211602, encodeId=5b1e2211602f3, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a> <a href='/topic/show?id=a1be1622242' target=_blank style='color:#2F92EE;'>#SGLT-2抑制剂#</a> <a href='/topic/show?id=bf511158e4b6' target=_blank style='color:#2F92EE;'>#固定比例胰岛素组合#</a> <a href='/topic/show?id=37021158e56e' target=_blank style='color:#2F92EE;'>#2024ADA#</a>, objectTitle=固定比例胰岛素组合，有效降低恶心等不良反应 | 2024 ADA, objectType=article, longId=831775, objectId=2060831e75fb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719305727122_92910.png, objectUrl=/article/show_article.do?id=2060831e75fb, replyNumber=0, likeNumber=100, createdTime=2024-06-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2060831e75fb, moduleTitle=固定比例胰岛素组合，有效降低恶心等不良反应 | 2024 ADA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2060831e75fb)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211391, encodeId=dc07221139107, content=<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a> <a href='/topic/show?id=1e95115803e7' target=_blank style='color:#2F92EE;'>#ADA2024#</a> <a href='/topic/show?id=10e011581471' target=_blank style='color:#2F92EE;'>#ZT002#</a>, objectTitle=每月一次，减重效果维持71天！GLP-1新药效果积极 | ADA 2024速递, objectType=article, longId=831444, objectId=761983144449, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240624/1719199471466_5579292.png, objectUrl=/article/show_article.do?id=761983144449, replyNumber=0, likeNumber=85, createdTime=2024-06-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=761983144449, moduleTitle=每月一次，减重效果维持71天！GLP-1新药效果积极 | ADA 2024速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=761983144449)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2207642, encodeId=999b220e642c7, content=<a href='/topic/show?id=bec66989e9a' target=_blank style='color:#2F92EE;'>#甲状腺癌#</a> <a href='/topic/show?id=4066981e99e' target=_blank style='color:#2F92EE;'>#降糖药#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=BMJ：热门降糖减重药增加甲状腺癌风险？重要证据来了, objectType=article, longId=828117, objectId=26f682811eaf, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240531/1717128921515_5579292.jpg, objectUrl=/article/show_article.do?id=26f682811eaf, replyNumber=0, likeNumber=89, createdTime=2024-05-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=26f682811eaf, moduleTitle=BMJ：热门降糖减重药增加甲状腺癌风险？重要证据来了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f682811eaf)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2205366, encodeId=7a75220536639, content=<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a> <a href='/topic/show?id=a1be1622242' target=_blank style='color:#2F92EE;'>#SGLT-2抑制剂#</a>, objectTitle=BMJ Open Diabetes Res Care：SGLT-2抑制剂和GLP-1受体激动剂作为三阶梯降糖药物对2型糖尿病降低患者心血管疾病和死亡率的益处, objectType=article, longId=826361, objectId=0f8482636136, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024236648_4754896.jpeg, objectUrl=/article/show_article.do?id=0f8482636136, replyNumber=0, likeNumber=87, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0f8482636136, moduleTitle=BMJ Open Diabetes Res Care：SGLT-2抑制剂和GLP-1受体激动剂作为三阶梯降糖药物对2型糖尿病降低患者心血管疾病和死亡率的益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f8482636136)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178005, encodeId=03b521e8005d3, content=<a href='/topic/show?id=31618386e18' target=_blank style='color:#2F92EE;'>#胰岛素#</a> <a href='/topic/show?id=dad4621545' target=_blank style='color:#2F92EE;'>#DPP-4抑制剂#</a> <a href='/topic/show?id=9d5d44888a9' target=_blank style='color:#2F92EE;'>#妊娠期糖尿病#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性, objectType=article, longId=807481, objectId=89b680e48114, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231229/1703830837087_5490734.jpg, objectUrl=/article/show_article.do?id=89b680e48114, replyNumber=0, likeNumber=125, createdTime=2023-12-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=89b680e48114, moduleTitle=JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b680e48114)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175621, encodeId=9d8b21e5621b3, content=<a href='/topic/show?id=51cbe247518' target=_blank style='color:#2F92EE;'>#直肠癌#</a> <a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=超120万人研究：这类降糖药或能降低癌症风险！, objectType=article, longId=805599, objectId=b118805599ac, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-at-work-PGMH47J.jpg, objectUrl=/article/show_article.do?id=b118805599ac, replyNumber=0, likeNumber=95, createdTime=2023-12-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b118805599ac, moduleTitle=超120万人研究：这类降糖药或能降低癌症风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b118805599ac)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118789, encodeId=3d6f2118e8947, content=<a href='/topic/show?id=f3ad840081f' target=_blank style='color:#2F92EE;'>#胰高血糖素样肽-1#</a> （<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>）为基础的药物，包括<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>（GLP-1RA）和<a href='/topic/show?id=788a24043af' target=_blank style='color:#2F92EE;'>#二肽基肽酶-4抑制剂#</a> （<a href='/topic/show?id=03d2622088' target=_blank style='color:#2F92EE;'>#DPP4i#</a>），是用于治疗<a href='/topic/show?id=d20f1090c2' target=_blank style='color:#2F92EE;'>#2型糖尿病#</a>的<a href='/topic/show?id=98e610556057' target=_blank style='color:#2F92EE;'>#肠促胰素类药物#</a>。除了肠促胰素效应外，GLP-1为基础的药物还具有<a href='/topic/show?id=98c0553894c' target=_blank style='color:#2F92EE;'>#抗炎#</a>作用。然而，既往一项研究报告使用DPP4i会增加<a href='/topic/show?id=2e6e6e0315d' target=_blank style='color:#2F92EE;'>#炎症性肠病#</a>（IBD）风险。, objectTitle=ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据, objectType=article, longId=762356, objectId=7d8be62356b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230111/361cfc26c42642a891ede2db100a3ffa.jpg, objectUrl=/article/show_article.do?id=7d8be62356b3, replyNumber=0, likeNumber=174, createdTime=2023-03-11, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=7d8be62356b3, moduleTitle=ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d8be62356b3)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1294052, encodeId=d42b1294052a8, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, objectType=article, longId=739436, objectId=f1a5e39436f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1a5e39436f8, replyNumber=0, likeNumber=102, createdTime=2022-09-17, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1a5e39436f8, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1a5e39436f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294051, encodeId=7185129405189, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, objectType=article, longId=723796, objectId=c62be2379617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62be2379617, replyNumber=0, likeNumber=0, createdTime=2022-04-09, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62be2379617, moduleTitle=Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62be2379617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294050, encodeId=c43c12940502a, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, objectType=article, longId=300317, objectId=525d30031e63, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525d30031e63, replyNumber=0, likeNumber=100, createdTime=2022-03-10, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525d30031e63, moduleTitle=JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525d30031e63)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294049, encodeId=6e2c1294049e2, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, objectType=article, longId=295500, objectId=4e5b295500be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5b295500be, replyNumber=0, likeNumber=84, createdTime=2022-02-13, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5b295500be, moduleTitle=BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5b295500be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294048, encodeId=91801294048cc, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, objectType=article, longId=293924, objectId=e7922939240b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7922939240b, replyNumber=0, likeNumber=87, createdTime=2022-01-14, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7922939240b, moduleTitle=JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7922939240b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294047, encodeId=bf70129404ea8, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, objectType=article, longId=220590, objectId=46c922059001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46c922059001, replyNumber=0, likeNumber=89, createdTime=2021-11-20, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46c922059001, moduleTitle=Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46c922059001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294046, encodeId=7bb61294046cd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, objectType=article, longId=220003, objectId=76552200039d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76552200039d, replyNumber=0, likeNumber=125, createdTime=2021-11-10, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76552200039d, moduleTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76552200039d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294045, encodeId=b884129404542, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, objectType=article, longId=217820, objectId=f24821e820ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24821e820ef, replyNumber=0, likeNumber=89, createdTime=2021-09-30, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24821e820ef, moduleTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24821e820ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294044, encodeId=794412940441b, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, objectType=article, longId=216263, objectId=a32e21626362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a32e21626362, replyNumber=0, likeNumber=83, createdTime=2021-08-26, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a32e21626362, moduleTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a32e21626362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, objectType=article, longId=213906, objectId=58312139068b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58312139068b, replyNumber=0, likeNumber=126, createdTime=2021-07-09, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58312139068b, moduleTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58312139068b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294042, encodeId=223c129404256, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=95, createdTime=2021-07-02, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294041, encodeId=e2c7129404147, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, objectType=article, longId=213289, objectId=5cdb21328936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cdb21328936, replyNumber=0, likeNumber=107, createdTime=2021-06-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cdb21328936, moduleTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cdb21328936)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GLP-1受体激动剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂# #青少年患者#

JAMA 子刊：青少年使用GLP-1受体激动剂的现状与共病特征分析

2024-10-23发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #GLP-1受体激动剂# #SGLT-2抑制剂# #固定比例胰岛素组合# #2024ADA#

固定比例胰岛素组合，有效降低恶心等不良反应 | 2024 ADA

2024-06-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#2型糖尿病# #GLP-1受体激动剂# #ADA2024# #ZT002#

每月一次，减重效果维持71天！GLP-1新药效果积极 | ADA 2024速递

2024-06-24发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#甲状腺癌# #降糖药# #GLP-1受体激动剂#

BMJ：热门降糖减重药增加甲状腺癌风险？重要证据来了

2024-05-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#2型糖尿病# #GLP-1受体激动剂# #SGLT-2抑制剂#

BMJ Open Diabetes Res Care：SGLT-2抑制剂和GLP-1受体激动剂作为三阶梯降糖药物对2型糖尿病降低患者心血管疾病和死亡率的益处

2024-05-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胰岛素# #DPP-4抑制剂# #妊娠期糖尿病# #GLP-1受体激动剂#

JAMA Intern Med：GLP-1受体激动剂和其他二线降糖药在妊娠早期的安全性

2023-12-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#直肠癌# #GLP-1受体激动剂#

超120万人研究：这类降糖药或能降低癌症风险！

2023-12-18发表于上海

showtest (审核中...)

前往app查看评论内容

全文收起 #胰高血糖素样肽-1# （#GLP-1#）为基础的药物，包括#GLP-1受体激动剂#（GLP-1RA）和#二肽基肽酶-4抑制剂# （#DPP4i#），是用于治疗#2型糖尿病#的#肠促胰素类药物#。除了肠促胰素效应外，GLP-1为基础的药物还具有#抗炎#作用。然而，既往一项研究报告使用DPP4i会增加#炎症性肠病#（IBD）风险。

ECCO 2023 | GLP-1为基础的药物与炎症性肠病风险：来自国家队列研究的真实世界证据

2023-03-11发表于上海

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Cardiovasc Diabetol：GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病的有效性和安全性

2022-09-17

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Cardiovasc Diabetol：DPP-4抑制剂、GLP-1受体激动剂和SGLT-2抑制剂对心肾结局的影响

2022-04-09

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

JAMA子刊：GLP-1受体激动剂与DPP-4抑制剂的使用与2型糖尿病和晚期慢性肾病患者死亡率的关系

2022-03-10

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

BM子刊：GLP-1受体激动剂治疗T2DM患者的真实体重变化、依从性和停药情况

2022-02-13

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

JAMA：GLP-1受体激动剂体重控制谁更强？索马鲁肽减重效果优于利拉鲁肽

2022-01-14

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Cardiovasc Diabetol：GLP-1受体激动剂VS基础胰岛素——用于2型糖尿病常规治疗后的心血管结局比较

2021-11-20

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析

2021-11-10

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益

2021-09-30

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率

2021-08-26

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平

2021-07-09

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

2021-07-02

heli0118 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响

2021-06-28

科室
- - 订阅+
  - 更多科室
工具
服务